Viking Therapeutics maintains a remarkably clean and conservative financial capital structure with virtually zero significant long-term debt on its corporate balance sheet. As a clinical-stage biopharmaceutical enterprise focused heavily on metabolic and endocrine diseases, the firm historically finances its research pipeline, preclinical studies, and extensive clinical trials through equity offerings, public stock issuances, and strategic cash reserves rather than relying on burdensome commercial loan obligations or interest-bearing debt facilities.